Facts and Figures
- The Shanghai Facility is located in the Minghang district of Shanghai, covering 58,000 square meters. There was a recent expansion for Onglyza.
- The Shanghai facility is a pharmaceutical plant that manufactures:
|Capital Investment (2009-2011)|
|Year||Contribution to tax base - pre-tax|
Examples of Local charitable contributions:
- Adopted the South China tiger (Panthera tigris amayensis) that is ranked one of the most endangered species worldwide by donating $12,500.
- Supported project "Charity Medical Card" by providing six million RMB (almost $1 million) worth of medicines in three years to 285 hospitals and community hygiene centers to help poor residents who have not been covered by the municipal medical issuance system.
- Donated 3,000,000 RMB worth (about $500,000) of Theragran JR to the poor pupils in the Shanghai area and DaYingBAng primary school in Yuexi county of Sichuan LiangZhou Yi, autonomous prefecture, to improve the health of children.
- Contributed $50,000 to The China Foundation for Hepatitis Prevention and Control (CFHPC) in support of a project entitled "Analysis of current hepatitis spreading situation and related issues in China."
Community and Social Progress
- Training of Trainers Program for Medical Personnel in Labor Intensive Factories in the Pearl River Delta: The project aimed to enhance the awareness of hepatitis prevention and treatment among medical personnel and workers in factories in the Pearl River Delta.
Partner areas: The Inno Community Development Organization
Coverage: 1,250 medical personnel and nearly 750,000 employees from 250 factories in the entire Pearl River Delta
Donation amount: U.S. $427K
- Prevention of Hepatitis B and Hepatitis C Transmission among High-Risk Groups in Shanghai: The two-year program focused on the disease education and promotion of prevention for high-risk groups in Shanghai. It provided targeted intervention projects for different high-risk groups. It also invited the School of Public Health of Fudan University to carry out third-party assessments of the entire initiative. Meanwhile, a systematic scheme for hepatitis prevention and control was sorted out, providing more information and references for partners such as local disease control centers.
Partner areas: The Shanghai Charity Foundation
Donation amount: U.S. $249K
- Survey on Hepatitis C Transmission in Yanbian Prefecture: This survey was designed to study the characteristics and status of hepatitis C transmissions in Yanbian, and to work out an effective policy to contain the spread of hepatitis C.
Partner: The Chinese Foundation for Hepatitis Prevention and Control
Coverage areas: Yanbian Prefecture of Jilin Province
Donation amount: U.S. $199K
- Public Education System for Hepatitis B and Hepatitis C in Haimen City: This project was intended to establish a public education system for hepatitis B and hepatitis C, to help reduce social discrimination in areas with high epidemic rates of hepatitis B, and improve the living standards of hepatitis B and liver cancer patients. The project benefited 1.03 million residents in Haimen city.
Partner: The Hepatitis B Foundation
Coverage areas: Haimen City of Jiangsu Province
Donation amount: U.S. $400K
- Study on Chinese Hepatitis C Patients’ Socioeconomic Burdens and Comprehensive Intervention: This study was aimed at promoting social empathy for hepatitis C patients and providing references for the health department to improve the accessibility of hepatitis C medicines.
Partner areas: The Wu Jieping Medical Foundation
Coverage: 35 hospitals in 16 provinces across China
Donation amount: U.S. $247K
- Shanghai Hepatitis C Education Project: The project was China’s first hepatitis C education project specially designed for the medical staff, hepatitis C patients and their dependents, with the aim to help improve the medical staff’s understanding of hepatitis C, increase hepatitis C patients’ screening rate and treatment rate, and strengthen patients’ immunities.
Partner: The Shanghai Charity Foundation
Coverage areas: Shanghai
Donation amount: U.S. $195K
- Rebuilt a road in the community and beautified the two sides along the road with total investment of U.S. $37,000.
- Evidence-based medical seminar to brief doctors about the latest clinic research and treatment practices.
- Live broadcasting of latest clinic research results through satellite to doctors in 20 cities.
- Education campaigns on chronic and common diseases in collaboration with major media in various provinces.
- Supported Gold Theragran Vitamin nutrition and health education campaign in 26 cities.
- Children’s health education campaign in Shanghai to promote health awareness among children in the city by engaging in child-friendly activities.
- Conducted Bufferin Drug Box program to promote OTC self-medication knowledge.
Awards and recognition:
- In 2009 and 2010, Bristol-Myers Squibb won the “Commitment to Philanthropy Award,” from Southern Weekly in association with some institutes such as the China Corporate Social Responsibility Research Center for two consecutive years.
- In 2009, Bristol-Myers Squibb Foundation’s Hepatitis Prevention and Treatment Project won the “Outstanding Contribution Award,” from the China Charity Federation.
- In 2009, Bristol-Myers Squibb was selected as one of “China’s Top 10 Green Enterprises” to receive the Corporate Social Responsibility Award from Fortune (Chinese Edition).
- In 2009, Bristol-Myers Squibb received the “30 Years of Reform and Opening – Society Citizen of Chinese Medicine,” awarded by the China Pharmaceutical Enterprise Management Association.
|Key Facility Environmental Performance Metrics 2012|
|Water Use||Liters 154,000,000|
Practices using local products and services:
- Shanghai developed more than 60 vendors inside China, some of which are able to provide their products worldwide.
SASS management has set several aggressive goals in these areas:
- Continuously improve Environment, Health & Safety (EHS) awareness of all employees on site, as well as contractors based on the conviction that education on EHS issues will improve performance in all areas.
- Achieve the "Three Zeros:" Zero fire, zero professional-related diseases, and zero professional-related injuries.
- Becoming an EHS leader in China's pharmaceutical industry by integrating EHS into all business phases and creating an accident-free work environment.
- Continuing to be an industry leader in ISO 14001 compliance.
Safety performance highlights:
- In Shanghai, EHS training is incorporated into the orientation program for employees new to the site and for employee rotation. This training covers the company's commitment to safety and environmental protection.
- As a standard practice, Shanghai conducts a comprehensive inspection and safety evaluation prior to purchasing a new machine or designing a new project, including consideration of GMP and EHS. Following this process, most hardware-associated hazards are eliminated at the design phase.
- As a result of the above best practices, Shanghai made measurable progress towards creating an accident-free work site.
From 2009 to 2011, the Shanghai facility achieved recognition as Shanghai Minhang Economic and Technological Development Zone Energy Saving Winning Business based on the following projects, among others.
- Upgrading two chillers to high efficiency equipment and environmental coolant.
- Utilizing variable frequency motors for the chiller pumps.
- Establishing two different air change frequencies for work time and non-work time for all existing and newly expanded areas.
- Converting office and warehouse lighting to Philips efficient tube.
- Reviewing water balance and changing part of water pipe system to enhance efficiency.
- Installing fuel economizer in boilers.
- Replacing heavy oil with light oil to reduce air pollution.
- Reusing reverse osmosis flushing water.
- Conducting cooling tower water blow down based on water quality analysis.
The Shanghai facility is dedicated to “cleaner production.” This refers to the continuous application of comprehensive prevention strategies to the production process and products to minimize the risks to mankind and the environment. The aim of cleaner production is to increase the resource utilization rate, reduce and avoid pollutants, protect and improve the ecological environment, ensure human health and promote the sustainable development of the economy and society.
The Shanghai facility has pursued this goal by:
- Increasing the serviceability and utilization rate of the equipment by expanding the production batch, and by continuous production;
- Limiting the disposal of pollutants;
- Adopting frequency conversion fans, water pumps and other energy-saving measures;
- Recycling raw materials and energy; and
- Upgrading old production flows, technologies and equipment, and developing green packaging materials.
Bristol-Myers Squibb procurement process sets environmental protection standards on raw materials, auxiliary materials and packaging materials and selects qualified suppliers according to the standards. By holding supplier conferences regularly, the company provides training on environmental health and safety for existing suppliers. Bristol-Myers Squibb also audits major suppliers on an annual basis to determine whether they have achieved ISO 14001 certification or have other systems/activities that support environmental compliance. Suppliers are reminded to comply with China's GHS and other EHS regulations.
Training and Communication on Environmental Protection
Every department of the Shanghai facility sends representatives for external training for ISO 14001 internal auditors, and carries out an internal training session every year. In 2011, the company organized several training sessions for administrative staff and operational personnel on hazardous chemicals, precursor chemicals and special equipment.
Facility Contact Information
Main site phone number